<DOC>
	<DOCNO>NCT02010567</DOCNO>
	<brief_summary>This trial enroll patient locally advanced rectal cancer ( resectable non-resectable ) .The phase Ib dose escalation portion trial design determine maximum tolerate dose ( MTD ) CRLX101 combine standard neoadjuvant therapy capecitabine ( Cape ) radiation therapy ( XRT ) . CRLX101 nanopharmaceutical ( NP ) formulation camptothecin . These result determine recommended phase II dose ( RP2D ) CRLX101 set . The phase II portion trial design evaluate efficacy safety CRLX101 RP2D , combine capecitabine radiation therapy prior surgery .</brief_summary>
	<brief_title>Neoadjuvant Chemoradiotherapy With CRLX-101 Capecitabine Rectal Cancer</brief_title>
	<detailed_description>This open label , single-arm , multi-center , Phase Ib/II study design evaluate CRLX101 , NP formulation camptothecin , dose combination capecitabine radiation therapy patient advance rectal carcinoma . The purpose Phase Ib portion study identify MTD CRLX101 add standard neoadjuvant chemo-radiotherapy . The MTD base rate dose-limiting toxicity ( DLT ) Phase Ib , assess via NCI 's CTCAE v4.0 toxicity criterion . The MTD assign RP2D trial . If CRLX101 safely administer combination capecitabine radiation dose &gt; /= 9 mg/m2 IV Phase Ib study , trial proceed Phase II . Patients Phase Ib study resectable disease treat RP2D include Phase II study population . The phase II study design evaluate efficacy regimen assess rate pathological complete response ( pCR ) monitoring safety tolerability . We anticipate accrual 25 patient per year Phase II study , slightly faster accrual 2-3 patient per month Phase Ib give broad inclusion criterion . During Phase Ib , evaluate safety determine MTD/RP2D CRLX101 + capecitabine ( Cape ) radiation therapy ( XRT ) patient rectal cancer use traditional 3+3 dose escalation design . Adverse event ( AEs ) evaluate via CTCAE version 4.0 . Patients Phase Ib also follow pathological response resectable disease . If CRLX101 safely administer combination capecitabine radiation dos ? 9 mg/m2 IV Phase Ib study , trial proceed Phase II primary objective estimate rate pCR . Non-metastatic patient resectable disease treat MTD/RP2D Phase Ib include Phase II study population . In Phase II , CRLX101 administer RP2D combination capecitabine radiation patient locally advanced rectal cancer total 5-6 week , depend total radiation dose . A total 3 dos CRLX101 administer every week . Surgery take place least 6 week completion chemoradiotherapy . For non-metastatic Phase I patient Phase II population , postoperative adjuvant therapy indicate regardless whether pCR achieve . While number regimen use adjuvant setting , national guideline specify one regimen . Given consistent application adjuvant therapy population , also plan follow Phase II patient disease free survival ( DFS ) overall survival ( OS ) .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . ECOG performance score ≤ 2 2 . Phase Ib II : surgical candidate , moderate highrisk pathologicallyconfirmed rectal cancer ( stage cT34N0 cT14N+ ) ; clinical staging endoscopic ultrasound ( EUS ) magnetic resonance imaging ( MRI ) permit . Phase Ib : Patients metastatic rectal cancer allow primary site meet eligibility criterion chemoradiotherapy recommend initial therapy symptom palliation multidisciplinary treating team Patients locally advance unresectable rectal cancer allow provide : There evidence rectovaginal , rectovesicular , rectointestinal fistulization Standard dose schedule chemoradiotherapy recommend initial therapy multidisciplinary treat team 3 . Age ≥18 year old 4 . Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day prior D1 treatment 5 . Recommendation undergo concurrent chemoradiation , determine treat physician 6 . Ability swallow oral medication 7 . As determined enrol physician protocol designee , ability patient understand comply study procedure entire length study 8 . Informed consent review sign Patients meet follow exclusion criterion able participate study : 1 . Grade 2 high diarrhea baseline unless deem investigator cause laxative prescribe symptomatic partial obstruction ( e.g . MiraLAX® ) 2 . Not deemed candidate concurrent chemoradiation medical reason , uncontrolled infection ( include HIV ) , uncontrolled diabetes mellitus cardiac disease , opinion treat physician , would make protocol unreasonably hazardous patient . 3 . Specific laboratory exclusion value , include : Hemoglobin &lt; 10.0 g/dL male ≤ 9.0 g/dL female ( transfusion allow achieve maintain level ) ANC &lt; 1,500/mm3 Platelet count &lt; 100,000/mm3 ALT AST &gt; 2.5 time upper level normal ( ULN ) Alkaline phosphatase &gt; 2.5 time ULN Total bilirubin &gt; 1.5 time ULN Creatinine clearance &lt; 50 mL/min INR &gt; 2 4 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 5 . History Gilbert 's syndrome 6 . Those require therapeutic anticoagulation coumarinderivative anticoagulant 7 . Unable provide inform consent 8 . Receiving concurrent cytotoxic , biologic agent ( ) investigational agent 9 . Patients `` currently active '' second malignancy nonmelanoma skin cancer , noninvasive bladder cancer , `` low risk '' adenocarcinoma prostate carcinoma situ cervix . Patients consider `` currently active '' malignancy complete therapy free disease ≥ 2 year . 10 . Previous pelvic radiation therapy 11 . Prior treatment topoisomerase I inhibitor ( i.e . irinotecan , topotecan )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>locally advanced rectal cancer</keyword>
	<keyword>locally advanced rectal cancer ( resectable )</keyword>
	<keyword>locally advanced rectal cancer ( non-resectable )</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>nanopharmaceuticle</keyword>
	<keyword>CLX101</keyword>
	<keyword>camptothecin</keyword>
	<keyword>capecitabine</keyword>
</DOC>